Literature DB >> 11353013

Activation of group III mGluRs inhibits GABAergic and glutamatergic transmission in the substantia nigra pars reticulata.

M Wittmann1, M J Marino, S R Bradley, P J Conn.   

Abstract

The GABAergic projection neurons of the substantia nigra pars reticulata (SNr) exert an important influence on the initiation and control of movement. The SNr is a primary output nucleus of the basal ganglia (BG) and is controlled by excitatory inputs from the subthalamic nucleus (STN) and inhibitory inputs from the striatum and globus pallidus. Changes in the output of the SNr are believed to be critically involved in the development of a variety of movement disorders. Anatomical studies reveal that metabotropic glutamate receptors (mGluRs) are highly expressed throughout the BG. Interestingly, mRNA for group III mGluRs are highly expressed in STN, striatum, and globus pallidus, and immunocytochemical studies have shown that the group III mGluR proteins are present in the SNr. Thus it is possible that group III mGluRs play a role in the modulation of synaptic transmission in this nucleus. We performed whole cell patch-clamp recordings from nondopaminergic SNr neurons to investigate the effect of group III mGluR activation on excitatory and inhibitory transmission in the SNr. We report that activation of group III mGluRs by the selective agonist L(+)-2-amino-4-phosphonobutyric acid (L-AP4, 100 microM) decreases inhibitory synaptic transmission in the SNr. Miniature inhibitory postsynaptic currents studies and paired-pulse studies reveal that this effect is mediated by a presynaptic mechanism. Furthermore we found that L-AP4 (500 microM) also reduces excitatory synaptic transmission at the STN-SNr synapse by action on presynaptically localized group III mGluRs. The finding that mGluRs modulate the major inputs to SNr neurons suggests that these receptors may play an important role in motor function and could provide new targets for the development of pharmacological treatments of movement disorders.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11353013     DOI: 10.1152/jn.2001.85.5.1960

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  27 in total

1.  Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson's disease.

Authors:  Matthew J Betts; Michael J O'Neill; Susan Duty
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

2.  Activation of group II metabotropic glutamate receptors induces long-term depression of excitatory synaptic transmission in the substantia nigra pars reticulata.

Authors:  Kari A Johnson; Colleen M Niswender; P Jeffrey Conn; Zixiu Xiang
Journal:  Neurosci Lett       Date:  2011-09-16       Impact factor: 3.046

3.  Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease.

Authors:  P J Austin; M J Betts; M Broadstock; M J O'Neill; S N Mitchell; S Duty
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 4.  Glutamate and GABA receptors and transporters in the basal ganglia: what does their subsynaptic localization reveal about their function?

Authors:  A Galvan; M Kuwajima; Y Smith
Journal:  Neuroscience       Date:  2006-10-23       Impact factor: 3.590

Review 5.  Driving cellular plasticity and survival through the signal transduction pathways of metabotropic glutamate receptors.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Faqi Li
Journal:  Curr Neurovasc Res       Date:  2005-12       Impact factor: 1.990

6.  Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment.

Authors:  Michael J Marino; David L Williams; Julie A O'Brien; Ornella Valenti; Terrence P McDonald; Michelle K Clements; Ruiping Wang; Anthony G DiLella; J Fred Hess; Gene G Kinney; P Jeffrey Conn
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-30       Impact factor: 11.205

7.  The metabotropic glutamate receptor 7 (mGluR7) allosteric agonist AMN082 modulates nucleus accumbens GABA and glutamate, but not dopamine, in rats.

Authors:  Xia Li; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2007-11-19       Impact factor: 5.250

8.  Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease.

Authors:  Jonathan W Dickerson; P Jeffrey Conn
Journal:  Neurodegener Dis Manag       Date:  2012-04-01

Review 9.  Therapeutic promise and principles: metabotropic glutamate receptors.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Jinling Hou
Journal:  Oxid Med Cell Longev       Date:  2008 Oct-Dec       Impact factor: 6.543

10.  Presynaptic external calcium signaling involves the calcium-sensing receptor in neocortical nerve terminals.

Authors:  Wenyan Chen; Jeremy B Bergsman; Xiaohua Wang; Gawain Gilkey; Carol-Renée Pierpoint; Erin A Daniel; Emmanuel M Awumey; Philippe Dauban; Robert H Dodd; Martial Ruat; Stephen M Smith
Journal:  PLoS One       Date:  2010-01-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.